Literature DB >> 15136456

Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung.

Jill M Siegfried1, James D Luketich, Laura P Stabile, Neil Christie, Stephanie R Land.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15136456     DOI: 10.1378/chest.125.5_suppl.116s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


× No keyword cloud information.
  4 in total

1.  The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis.

Authors:  Eileen L Heinrich; Tonya C Walser; Kostyantyn Krysan; Elvira L Liclican; Jeanette L Grant; Nicole L Rodriguez; Steven M Dubinett
Journal:  Cancer Microenviron       Date:  2011-09-16

2.  HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer.

Authors:  Lynn M Knowles; Laura P Stabile; Ann Marie Egloff; Mary E Rothstein; Sufi M Thomas; Christopher T Gubish; Edwina C Lerner; Raja R Seethala; Shinsuke Suzuki; Kelly M Quesnelle; Sarah Morgan; Robert L Ferris; Jennifer R Grandis; Jill M Siegfried
Journal:  Clin Cancer Res       Date:  2009-05-26       Impact factor: 12.531

3.  Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.

Authors:  Laura P Stabile; Mary E Rothstein; Phouthone Keohavong; Jide Jin; Jinling Yin; Stephanie R Land; Sanja Dacic; The Minh Luong; K Jin Kim; Austin M Dulak; Jill M Siegfried
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

4.  Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice.

Authors:  Laura P Stabile; Mary E Rothstein; Phouthone Keohavong; Diana Lenzner; Stephanie R Land; Autumn L Gaither-Davis; K Jin Kim; Naftali Kaminski; Jill M Siegfried
Journal:  Cancers (Basel)       Date:  2010-12-01       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.